Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clesrovimab for RSV Prevention in a Human Challenge Study
NCT04086472Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
A Phase 2 trial of clesrovimab-cfor in respiratory syncytial virus infection (RSV), sponsored by Merck & Co.. Started Oct 2019; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04086472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086472.